References
- Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, et al. Safety of tacrolimus in patients with rheu-matoid arthritis: long-term experience. Ftheumatology (Oxford) 2004;43(8):992–9.
- Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppres-sive agent, in the treatment of rheumatoid arthritis in elderly pa-tients. Ftheumatology (Oxford) 2006;45(4):441–4.
- Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 2003; 48(12):3328–37.
- Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo con-trolled dose-finding study. J Ftheumatol 2004;31(4243–51.
- Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain A, et al. Neurologic complications of FK 506. Transplant Proc 1991;23(6):3175–8.
- Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, et al. Adverse effects associated with the use of FK 506. Trans-plant Proc 1991;23(6):3105–8.
- Frank B, Perdrizet GA, White HM, Marsh JW, Lemann W, Woodle ES. Neurotoxicity of FK 506 in liver transplant recipients. Transplant Proc 1993;25(2):1887–8.
- Shutter LA, Green JP, Newman NJ, Hooks MA, Gordon RD. Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation. Neurology 1993;43(11):2417–8.
- Mueller AR, Platz KP, Schattenfroh N, Bechstein WO, Christe W, Neuhaus P. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. Transpl Int 1994;7 Suppl 1:S37–42.
- Trocha K, Winkler M, Haas J, Ftinge B, Wurster U, Ehrenheim C. Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin. Transpl Int 1994;7 Suppl 1:S43–9.
- Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA. FK506-induced neurotoxicity in liver transplantation. Ann Neurol 1994;35(4): 498–501.
- Small SL, Fukui MB, Bramblett GT, Eidelman BH. Immunosup-pression-induced leukoencephalopathy from tacrolimus (FK506). Ann Neurol 1996;40(4):575–80.
- Singh N, Bonham A, Fukui M. Immunosuppressive-associated leu-koencephalopathy in organ transplant recipients. Transplantation 2000;69(4):467–72.
- Veroux P, Veroux M, Puliatti C, Morale W, Cappello D, Valvo M, et al. Tacrolimus-induced neurotoxicity in kidney transplant recipi-ents. Transplant Proc 2002;34(8):3188–90.
- Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, et al. Tacrolimus-associated posterior reversible encephalopa-thy syndrome after allogeneic haematopoietic stem cell transplan-tation. Br J Haematol 2003;122(1):128–34.
- Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthri-tis Rheum 2003;48(10):2763–8.
- Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002;46(8):2020–8.
- Bottiger Y, Brattstrom C, Tyden G, Sawe J, Groth CG. Tacrolimus whole blood concentrations correlate closely to side-effects in re-nal transplant recipients. Br J Clin Pharmacol 1999;48(3):445–8.
- Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients: correlation with clinical events and side ef-fects. Transplantation 1994;57(4):519–25.
- Mueller AR, Platz KP, Bechstein WO, Schattenfroh N, Stoltenburg-Didinger G, Blumhardt G, et al. Neurotoxicity after orthotopic liver transplantation: a comparison between cyclospo-rine and FK506. Transplantation 1994;58(2):155–70.